Introduction

Breast cancer ranks as the most common form of female malignancy in several geographical areas of the world. Statistics in 2010 showed the highest incidence of breast cancer compared to other types of cancer among women in Thailand (National Institute, 2012).

The major approaches currently being used in the management of this type of cancer include surgery, radiation, and chemotherapy. These therapeutic approaches are however unimpressive, due mainly to their toxicity, immune-suppression, mutagenicity, carcinogenicity, and drug resistance. Furthermore, most of these approaches are unaffordable to patients from developing countries. A large number of cancer patients therefore, usually seek alternative treatments which they find more effective with fewer side effects and also less expensive. Traditional medicine has been recognized as an alternative treatment approach for cancer patients, particularly those with advanced stage cancer who do not find hope in treatment through modern medicine. Very commonly, cancer patients are treated with a mixture of herbs or herbal decoction, concurrently with some form of ritualistic ceremony and incantation.

One of the most well-known Thai folkloric remedies for treatment of various types of cancer which consists of a mixture of various parts from five plant, five animal species, and an artifact has been prescribed to cancer patients by traditional medicine practitioner Dr. Sommai Thongprasert for more than 40 years. The remedy has been used as an adjunct therapy to modern medicine. It is claimed to be well-tolerated and exceptionally well-tolerated and exceptionally

Abstract

The study aimed to evaluate immune-stimulating effects of a well-known Thai folkloric remedy when used for adjuvant therapy with conventional chemotherapeutics for treatment of breast cancer. Immunostimulating influence of the remedy (215 mg/kg body weight per day) on NK cell activity and TNF-α release from the monocytes/macrophages were investigated in a total of 15 healthy women and 13 female patients with breast cancer (Group 1). The effect of breast tumor surgery on NK cell activity was further investigated in 18 female patients with breast cancer (Group 2). NK cell cytotoxic activity was determined by chromium release cytotoxic assay using K562, an erythroleukemic cell line. TNF-α release from monocytes/macrophages separated from blood samples was determined through a biological assay using actinomycin D-treated L929 mouse fibroblast cells in the presence and absence of LPS. Baseline NK cell activity of the monocytes/macrophages separated from Group 2 patients expressed as %cytotoxicity was significantly lower than in the healthy subjects at E:T ratios of 100:1 and 25:1. In healthy subjects, there was no change in NK cell cytotoxic activity (%cytotoxicity or LU) following 1 and 2 weeks of treatment with the remedy compared with the baseline at various E:T ratios but the binding activity (%binding) was significantly increased after 2 weeks of treatment. The addition of one or two conventional chemotherapeutic regimens did not significantly reduce the NK cytotoxic activity but did affect release of TNF-α in both unstimulated and LPS-stimulated samples. Surgery produced a significant suppressive effect on NK cell activity. The use of the remedy as an adjunct therapy may improve therapeutic efficacy and safety profiles of conventional chemotherapeutic regimens through stimulation of the immune system in cancer patients.

Keywords: Thai folkloric remedy - breast cancer - NY cells - immunostimulatory influence

Immunostimulating Effect of a Well-known Thai Folkloric Remedy in Breast Cancer Patients

Piengpen Thisoda¹, Kanchana Ketsa-ard¹, Sommai Thongprasert², Molvibha Vongsakul³, Pornthipa Picha⁴, Juntra Karbwang⁵, Kesara Na-Bangchang⁶*

¹Department of Pharmacology, Faculty of Medicine, Siriraj Hospital, ²Department of Microbiology, Faculty of Science, Mahidol University, ³Department of Research, National Cancer Institute, Ministry of Public Health, Bangkok, ⁴Cancer Clinic, Singburi Province, ⁵Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand, ⁶Department of Clinical Product Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan *For correspondence: kesaratmu@yahoo.com

Asian Pacific J Cancer Prev, 14 (4), 2599-2605
effective for the treatment of breast cancer when used as adjuvant therapy with conventional chemotherapeutic agents. The use of this remedy is claimed to significantly prolong life, reduce suffering, and improve appetite and body weight that result in the promotion of quality of life. Its reputation spreads to cancer patients in the neighboring countries such as Singapore and Malaysia. A preliminary study in vitro and in animal models demonstrated the promising anticancer and immunostimulating activities of this remedy without cytotoxicity in vitro (Na-Bangchang et al., 2012). The aim of this study was to evaluate the immunostimulating effect of this remedy when used as an adjuvant therapy with conventional chemotherapeutics for the treatment of breast cancer patients.

Materials and Methods

Chemicals and reagents

Commercial grade methanol and hydrochloric acid were purchased from RCI Labscan Co. Ltd. (Pathumwan, BKK, THA). Eagle’s Minimum Essential Medium (MEM), Hank Balance Salt Solution (HBSS), TNF-α, and fetal bovine albumin were purchased from Gibco BRL Life Technologies (Grand Island, NY, USA). Penicillin and streptomycin were purchased from Difco (Baltimore, MD, USA). Articaine was donated by Articaine International Co. Ltd., MS, USA. The dark brown lyophilized remedy (6.0%, whole part), Clinacanthus nutans (Phaya Yor or Phaya Pong Thong, Acanthaceae family, 3.5%, stems and leaves), Canna indica (Puttara, Cannaceae family, 60.0%, rhizomes), Smilax corbularia (Kha-Quen, Smilacaceae family, 7.0%, rhizomes), and (b) Animals: Manis javanica (Nim, 5.0%, scales), Hystrix brachyuran (Menn, 5.0%, spines), Damonia subtrijuga (Tao Naa, 9.5%, carapaces), Dasyatis spp. (1.5%, spines), Trionyx cartilagineus (Ta Pabb Nam, 3.5%, sternums), and (c) an artifact (a small piece 6x6 cm² of bamboo bamboo used for holding water called “Kru”).

Preparation of plant extracts

One set of the remedy consists of a mixture of parts from five plants, five animals, and an artifact as follows: (a) Plants: Polygala chinesis (Ya Peek Kaai Dam, Polygalaceae family, 6.0%, whole part), Ammania baccifera (Fai Duen Haa, Lythraceae family, 6.0%, whole part), Clinacanthus nutans (Phaya Yor or Phaya Pong Thong, Acanthaceae family, 3.5%, stems and leaves), Canna indica (Puttara, Cannaceae family, 60.0%, rhizomes), Smilax corbularia (Kha-Quen, Smilacaceae family, 7.0%, rhizomes), and (b) Animals: Manis javanica (Nim, 5.0%, scales), Hystrix brachyuran (Menn, 5.0%, spines), Damonia subtrijuga (Tao Naa, 9.5%, carapaces), Dasyatis spp. (1.5%, spines), Trionyx cartilagineus (Ta Pabb Nam, 3.5%, sternums), and (c) an artifact (a small piece 6x6 cm² of bamboo bamboo used for holding water called “Kru”).

Information on plant species, parts used, including dose regimen used for the treatment of mammary cancer was kindly provided by Dr. Sommai Thongprasert. Plant materials were grown in various parts of Thailand and collected during particular seasons. Authentication of plant materials were carried out at the herbarium of the Department of Forestry, Bangkok, Thailand where the herbarium vouchers have been kept. All materials were washed thoroughly with water and cut into small pieces before being mixed in a pot (60 cm in diameter). Preparation of the water extract of the remedy was performed by boiling all materials in 10 litres of water at 100°C until the extract (decoction) evaporated to a volume of 0.5 litre. The collected decoction was filtered through a filter paper (Whatman number 1) under vacuum and centrifuged at 7,000 xg for 30 min (HTS International Equipment Co. Ltd., MS, USA). The process was repeated daily for 15 consecutive days. The decoction was concentrated by evaporation under reduced pressure at 55-65°C in a vacuum evaporator (Eyela, Tokyo Rikakai Co. Ltd., Tokyo, Japan). All of the 15-day concentrates were pooled and lyophilization was applied for complete dryness (Vertris, Research Equipment Gardiner Co. Ltd., NY, USA). The dark brown lyophilized remedy was ground into powder and stored at 4°C until use. The average dry weight of lyophilized powder obtained from each set of the remedy following a 15-day water extraction was 193 gram. Assuming the average patient’s body weight of 60 kg, the therapeutic prescribed dose in humans is approximately 215 mg/kg body weight/day.

Human subjects and study design

Approval of the study protocol was obtained from the Ethics Committee of Mahidol University, Bangkok, Thailand.

Healthy subjects: A total of 15 healthy female subjects aged 30-43 yrs old, weighing 45-55 kg, who had no history of breast diseases, diabetes mellitus, hypertension, and allergic diseases were included in the study. All had no history of previous drug administration for at least two weeks before and during the study period. The investigation of the effect of the remedy on NK cell activity was performed on 8 subjects. Heparinized blood (10 ml) was collected from all of them via venipuncture once a week before breakfast for three consecutive weeks to establish the baseline NK cell activity status. Administration of the first dose of the remedy (a daily dose of 215 mg/kg body weight for two weeks) started after the last blood collection on week 3. All volunteers were healthy as verified by physical examinations and laboratory tests (hematology and biochemistry).

Patients with breast cancer: The study was conducted on two groups of breast cancer patients (31 females). The diagnosis of breast cancer in both groups was through clinical examination and/or ultrasonography. Group 1 patients (13 females, aged 32-60 yrs old) received treatment with the remedy in combination with conventional chemotherapeutics at the Dr. Sommai Cancer Clinic, Singburi Province, Thailand. Five cases had previously been confirmed with the diagnosis of mammary cancer (adenocarcinoma) by histopathological examination of the biopsy specimen, 7 cases had previously undergone definitive clinical diagnosis of breast cancer (tumor diameter 1.5-4.0 cm) and later on confirmation of adenocarcinoma was done by histopathology, and 1 case had previously received treatment with modified radical mastectomy together with 6 cycles of adjuvant chemotherapy (Table 1). Treatment regimen for patients in this group consisted of the remedy (a daily dose of 215 mg/kg body weight for 24 weeks) in combination with conventional chemotherapeutics (cyclophosphamide, tamoxifen, mitomycin C-2, 5-fluourouracil, and prednisolone) as summarized in Table 2.

Group 2 patients (18 females, aged 35-68 years old) underwent modified radical mastectomy with auxiliary lymph node dissection, followed by adjunct treatment with conventional chemotherapeutics (FAC: 5-fluourouracil,
Asian Pacific Journal of Cancer Prevention, Vol 14, 2013

Immunostimulating Effect of a Well-known Thai Folkloric Remedy in Breast Cancer Patients

Table 1. Characteristics of Group 1 Patients (13 cases) who Received Treatment at Dr. Sommai Cancer Clinic, Singhaburi Province, Thailand

| Patient No. | Age (years) | Clinical description of mammary cancer |
|-------------|-------------|---------------------------------------|
| 1           | 32          | Post-biopsy with residual tumor (1 cm in diameter) |
| 2           | 35          | Post-biopsy |
| 3           | 39          | Post-biopsy |
| 4           | 48          | Post-biopsy |
| 5           | 60          | Post-biopsy |
| 6           | 42          | Tumor (3 cm in diameter) with nipple retraction, confirmed breast cancer (adenocarcinoma) by tissue biopsy after treatment. |
| 7           | 49          | Tumor (4 cm in diameter) with nipple retraction, confirmed breast cancer (adenocarcinoma) by tissue biopsy after treatment. |
| 8           | 34          | Tumor (2.5 cm in diameter) with nipple retraction, confirmed breast cancer (adenocarcinoma) by tissue biopsy after treatment. |
| 9           | 42          | Tumor (3 cm in diameter) with nipple retraction, confirmed breast cancer (adenocarcinoma) by tissue biopsy after treatment. |
| 10          | 32          | Tumor (1.5 cm in diameter) with irregular surface and fixed to chest wall, confirmed breast cancer (adenocarcinoma) by tissue biopsy after treatment. |
| 11          | 32          | Tumor (2 cm in diameter) with irregular surface and fixed to chest wall, confirmed breast cancer (adenocarcinoma) by tissue biopsy after treatment. |
| 12          | 35          | Tumor (2 cm in diameter) with irregular surface and fixed to chest wall, confirmed breast cancer (adenocarcinoma) by tissue biopsy after treatment. |
| 13          | 48          | Post-NRM and chemotherapy of 6 cycle with palpable lymph node |

Median 36 (range 32-60)

Table 2. Treatment Regimen in Patients with Breast Cancer in Group 1. The Folkloric Remedy was Given at a Dose of 500 ml per day for 24 Weeks (6 months)

| Day of treatment | Dose regimen/Blood collection |
|------------------|------------------------------|
| Day 14 (Week 2)  | Blood sample collection Folk remedy+Start and continue A |
| Day 28 (Week 4)  | Blood sample collection Folk remedy+Continue A+Start B |
| Day 42 (Week 6)  | Blood sample collection Folk remedy+Continue A+B |
| Week 6-24        | Blood sample collection Folk remedy |

Assessment of the effect on NK cell activity

Baseline NK cell activity of the effector NK cells (plastic non-adherence cells) was investigated in all healthy women (15 cases) and patients with breast cancer (31 cases) using the standard chromium-release cytotoxic assay (Pross et al., 1981) with modifications. The effect of the remedy when used alone or in combination with conventional chemotherapeutics on NK cell cytotoxic activity was investigated only in 12, 5, and 3 patients from Group 2 following treatment with the remedy alone, remedy in combination with one (A), and two (A+B) conventional chemotherapeutic regimens, respectively. Due to limitation of blood sample quantity, the effect of surgery on NK cell activity was accomplished in only 4 patients from Group 2.

Preparation of effector cells: Mononuclear cells were separated from peripheral blood samples (Boyum, 1968) with slight modifications under aseptic condition. In brief, the mononuclear cell suspension was allowed to adhere to plastic petri-dish at a density of 2x10^8 cells/cm^2 for 1 h in a humidified 37°C incubator with 5%CO₂. Non-adherent cells were collected through centrifugation (400 xg for 10 min). Cell pellets were resuspended in a RPMI 1640 medium and cell number was adjusted to 1x10^5 cells/ml. The viability of effector cells population as determined by tryphan blue exclusion was >95%. The adherent cells were removed from the surface of the dishes by incubation with a RPMI 1640 medium supplemented with 10% heat-activated fetal bovine serum and 5 mM EDTA (RPMI 1640 complete medium) at 37°C in 5%CO₂ incubator for 30 min. Cells were separated through centrifugation at 800 xg for 5 min. Cell pellets were resuspended in a RPMI 1640 complete medium and cell number was adjusted to 5x10^6 cells/ml. These cells were identified by esterase staining as monocytes/macrophages.

NK cell cytotoxicity assay: K562, an erythroleukemic cell line derived from a pleural effusion of a patient with chronic myelocytic leukemia in blast crisis (Lozzio and Lozzio, 1977), was used as the target cell for NK cytotoxic assay. The cells were maintained in a RPMI 1640 complete medium. Viability of the cells was checked by tryphan blue dye exclusion. The assay was performed in triplicates in a standard 96-well round-bottom tissue culture plates (Nunc, Intermed Co. Ltd., Copenhagen, Denmark) in a total volume of 200 μl. 51Cr-labeled K562 cells (1x10^6 cells/100 μl) were added into each well and the effector: target (E:T) cell ratios of 100:1, 50:1, 25:1, and 12.5:1 were prepared. Control wells for measuring spontaneous chromium release contained 100 μl of 1x10^6 target cells and 100 μl of a RPMI 1640 complete medium. Maximum releasable chromium was determined by adding 100 μl of 1x10^4 51Cr-labelled target cells to 100 μl of Triton X-100. 51Cr released from spontaneous and maximum release wells were simultaneously determined in each experiment. The plates were centrifuged at 50 xg for 5 min and incubated at 37°C in a humidified 5%CO₂ incubator for 4 h. At the end of the incubation period, doxorubicin, and cyclophosphamide given 3-weekly for 6 cycles at the Ramathibodi Hospital, Bangkok, Thailand. Inclusion criteria included stage II infiltrating breast adenocarcinoma, with no previous or concurrent cancer of other organs, diabetes mellitus, hypertension, allergic diseases, and with no previous treatment with radiation, chemotherapeutics or hormones.

Prior to the treatment, full physical and clinical examination were performed on patients of both groups. Heparinized blood samples (10 ml each) were collected from all patients before the administration of each treatment period for the assessment of NK cell cytotoxicity and TNF-α release activity (only Group 1). In addition, chest x-ray and laboratory investigation (hematology, biochemistry, and urinalysis) were performed on Group 2 patients.
cell supernatant in each well was separated through the centrifugation of the plates at 50 xg (4°C) for 10 min. An aliquot of 100 μl of supernatant was collected into a plastic tube and radioactivity was measured using a gamma counter (1260 Multigamma II. LKB, Stockholm, Sweden). NK cell cytotoxic activity was expressed as % cytotoxicity and lytic unit (LU: the number of effector cells required to cause 50% lysis of target cell) per 10² cells (Cerottini and Brenner, 1974). The cytotoxic activity was calculated according to the formula: %Cytotoxic activity = [(Experimental release - Spontaneous release) x 100/ (Maximum release - Spontaneous release)]

Experimental release is the mean count per minute (cpm) of supernatant from the quadruplicate wells containing a mixture of effector cells and labeled target cells. Maximum release is the mean cpm of supernatant from the labeled target cells incubated with 20% Triton X-100. Spontaneous release is the mean cpm of supernatant from the labeled target cells incubated in complete RPMI 1640 medium.

Assessment of the stimulatory effect on TNF-α release

L929, a transformed cell line originally derived from the C3H strain of mouse fibroblast was used as the target cell for the measurement of TNF-α activity of the monocytes/macrophages separated from 6 healthy subjects and 7 breast cancer patients in Group 1 before and after treatment with the remedy and remedy in combination with therapeutic regimen A. The cells were grown as an adherent monolayer in a RPMI 1640 in a sterile plastic disposable tissue culture flask (75 ml, Nunc, Copenhagen, Denmark) and sub-cultured every 3 days. TNF-α released from the cells was determined by a biological assay using actinomycin D-treated L929 mouse fibroblast cells in the presence (activated) and absence (non-activated) of LPS (Escherichia coli 0111: B4) for 24 h (Ruff and Gifford, 1980). The assay was performed in triplicates. Briefly, L929 cells (3x10⁵ in 100 μl RPMI 1940 medium) were seeded into 96-well flat-bottom tissue culture plates and allowed to grow for 24 h. On the day of the assay, the culture medium was discarded and two-fold serial dilutions of the culture supernatant, recombinant TNF-α, and 1 μg/ml actinomycin D were added (final volume 200 μl/well). The control wells contained L929 cells culture supernatant and 1 μg/ml of actinomycin D. Following 18 h of incubation (37°C, in a humidified 5% CO₂), the fluid in each well was discarded and the monolayer cells were washed three times with PBS to remove dead and non-adherent cells. The remaining cells were stained with 0.5% crystal violet in 25% methanol, washed with distilled water, and solubilized with 100 μl of acidified methanol (100 mM in hydrochloric acid). The absorbance was measured at 540 nm using a multi-scanning ELISA reader (Titertek Multoskan MCC/340 MK II, Flow Laboratories, Geneva, Switzerland). Percent cytotoxic activity was used to indicate TNF-α released from the cells according to the formula: Cytotoxicity (%) = [(1-OD₅₄₀ Experiment) x 100/ OD₅₄₀ Control].

Statistical analysis

All quantitative variables are presented as median (range). Comparison of all quantitative variables between the two groups was performed using Mann-Whitney U test and between pre- and post-treatment was by Wilcoxon signed rank test (SPSS version 11). Statistical significance level was set at α=0.05 for all tests.

Results

Effect of the remedy on NK cell activity

Baseline NK cell activity: NK cell activity measured by standard chromium-release cytotoxic assay of healthy women (15 cases) and patients with breast cancer in Group 1 (13 cases) and Group 2 (18 cases) before treatment is shown in Table 3. The cytotoxic activity of the target K562 cells was decreased by increasing the dilution of the effector cells from 100:1 to 12.5:1: in all groups. The NK cell cytotoxic activity expressed as either % cytotoxicity or lytic unit (LU) of the monocytes/macrophages separated from Group 1 breast cancer patients was similar to that of the healthy subjects at all E:T ratios. The NK cell activity of the monocytes/macrophages separated from Group 2 patients expressed as % cytotoxicity was significantly lower than the healthy subjects at the E:T ratios of 100:1 and 25:1.

Effect of the remedy alone and in combination with conventional chemotherapeutics on NK cell activity

Healthy subjects: The cytotoxic activity of the monocytes/macrophages separated from the blood of healthy subjects following treatment with the remedy for 1 or 2 weeks was decreased with the increasing dilution of the effector cells from 100:1 to 12.5:1. There was no change in NK cell cytotoxic activity (expressed as either % cytotoxicity or LU) following 1 and 2 weeks of treatment with the remedy and compared with the baseline at various
E:T ratios was significantly increased after 2 weeks of treatment with the remedy (Table 3). All volunteers were healthy as verified by physical examinations and laboratory tests performed on each subject before each treatment period.

Mammary cancer patients: The NK cell cytotoxic activity of the monocytes/macrophages separated from the blood of Group 1 patients with breast cancer was investigated after 2 weeks of treatment with the extract alone (12 cases) or when given in combination with one (chemotherapeutic regimen A: 5 cases) or two (chemotherapeutic regimen B: 3 cases) conventional chemotherapeutic regimens. The lytic unit and cytotoxic activity (%) at the E:T ratios of 100:1, 50:1, and 25:1:1 was significantly increased after 2 weeks of treatment with the remedy alone compared with the pre-treatment level. The decline in the activity when one or two conventional chemotherapeutic regimens was added was not statistically significant (Table 3).

Effect of surgery on NK cell activity
The effect of surgery on NK cell activity was also investigated in 4 patients in Group 2. Surgery produced a significant suppressive effect on the host immunity, with a significant reduction of cytotoxic activity (% cytotoxicity at almost all E:T ratios, and lytic unit) (Table 3).

Effect of the remedy on TNF-α release in healthy subjects
The specificity of the assay method was demonstrated by the detection of TNF-α in both culture supernatant of unstimulated and LPS-stimulated monocytes/macrophages but not in the culture supernatant of lymphocytes either with or without LPS stimulation. Cultured monocytes spontaneously released modest levels of TNF-α when cultured with 10 ng/ml LPS. Median (range) TNF-α level released from LPS-stimulated monocytes from 6 healthy subjects was 10.40 (0.40-18.98) pg/ml.

TNF-α released by monocytes/macrophages isolated from blood of patients with breast cancer in response to treatment
TNF-α released from the monocytes/macrophages (LPS-stimulated and unstimulated) in response to treatment was investigated in 6 healthy subjects and 7 patients with breast cancer in Group 1 before and after the treatment with the remedy and the remedy in combination with chemotherapeutic regimen A.

Healthy subjects: TNF-α activity was detected in both culture supernatant of unstimulated and LPS-stimulated monocytes but not in the culture supernatant of lymphocytes either with or without LPS stimulation indicating specificity of the assay. Cultured monocytes spontaneously released modest levels of TNF-α but with a significant level following stimulation with 10 ng/ml LPS [median (range) = 10.40 (9.02-12.04) pg/ml].

Breast cancer patients: TNF-α released from the unstimulated monocytes was undetectable in 4 subjects (No. 1, 5, 9, and 11). The levels in the other three cases were 0.180, 0.196, and 0.226 pg/ml. Following treatment with the remedy for 2 weeks, the level was increased in all of the seven cases [median (range) = 4.4 (0.48-1.80 pg/ml)]. The addition of chemotherapeutics to the treatment schedule decreased the release of TNF-α in 2 cases whose monocytes/macrophages were available for the assay (0.440 and < 0.124 pg/ml) (Figure 1). The addition of LPS stimulated the release of TNF-α in five cases including those previously inactive to LPS-stimulation at pre-treatment (No. 5 and 9) compared to the unstimulated

Table 3. NK Cell Activity as Indicated by Cytotoxicity (% cytotoxicity at various E:T ratios and lytic unit) of the Monocytes/Macrophages Isolated from Blood Samples Collected from Healthy Female Subjects, Group 1 (Dr. Sommai Cancer Clinic, Singburi Province, Thailand) and Group 2 (Ramathibodi Hospital, Bangkok, Thailand) Mammary Cancer Patients at Baseline, and Following Treatment with the Remedy Alone, or in Combination with Chemotherapeutic Regimen A and B. Data are Presented as Median (range)

| Healthy Subjects (n=15) | Baseline | Pre-treatment | 1 | 2 |
|-------------------------|---------|---------------|---|---|
|                        | (n=15)  | (n=15) | (n=15) | (n=15) |
| **Cytotoxicity:**       |         |         |         |         |
| 100:1                   | 74.47   | 74.88   | 73.38   | 73.13   |
| (71.13-46.02)           | (72.55-76.58) | (71.88-75.69) | (70.56-75.02) |
| 50:1                    | 62.67   | 63.75   | 64.75   | 64.38   |
| (60.63-64.25)           | (60.34-65.02) | (61.08-67.89) | (62.67-68.04) |
| 25:1                    | 46      | 47.25   | 49.25   | 50      |
| (45.49-47.02)           | (45.01-49.02) | (45.59-53.78) | (42.49-45.12) |
| 12.5:1                  | 26.4    | -       | -       | -       |
| (24.16-28.23)           |         |         |         |         |
| Lytic unit (LU/10⁶ cells) | 34.14   | 35.79   | 42.71   | 36.75   |
| (31.98-36.05)           | (32.98-37.66) | (40.98-44.78) | (33.80-40.14) |

| Breast Cancer Patients | Baseline | Pre-treatment | Remedy A alone for 2 weeks | Remedy B + Chemotherapeutic regimen A | Remedy B + Chemotherapeutic regimen A+B | Baseline Post-Surgery |
|------------------------|---------|---------------|-----------------------------|-------------------------------------|----------------------------------------|------------------------|
|                        | (n=13)  | (n=15) | (n=15) | (n=5) | (n=3) | (n=18) | (n=4) |
| **Cytotoxicity:**      |         |         |         |         |         |         |         |
| 100:1                  | 72.23   | 52.5   | 76.42* | 71.2   | 67.67   | 69.89** | 70.75   |
| (73.60-80.41)          | (66.95-72.12) | (66.35-72.15) | (66.51-71.11) | (66.33-71.19) |
| 50:1                   | 59.62   | 59.75  | 66.92* | 56.17  | 54.33   | 58.5    | 55.00*** |
| (63.22-61.02)          | (53.34-57.78) | (50.55-53.19) | (56.01-60.25) | (53.12-56.12) |
| 25:1                   | 44.23   | 44.58  | 51.83* | 42.17  | 39      | 41.11** | 35.50*** |
| (42.49-45.12)          | (41.55-48.72) | (41.28-43.01) | (40.11-42.18) | (34.41-39.02) |
| 12.5:1                 | 28.33   | 39.67  | 35.33  | 23     | 29      | 26.47   | 19.50*** |
| (25.23-30.18)          | (33.65-42.12) | (33.63-26.99) | (19.49-25.02) | (17.48-23.86) |

Statistically significant difference compared with baseline *p<0.01, Wilcoxon Signed Rank test. **p<0.01, Mann-Whitney U test. ***p<0.001, Wilcoxon Signed Rank test. ****p<0.05, Wilcoxon Signed Rank test.
monocytes [median (range) = 12.0 (4.40-28.80) pg/ml] (Figure 1). The other two cases (No. 12 and 13) whose monocytes had previously been highly active to LPS-stimulation became less active following treatment with the remedy (10.80 vs. 30.00 and 12.00 vs. 17.20 pg/ml, respectively). The addition of one chemotherapeutic drug to the treatment schedule of the remedy decreased the release of TNF-α in both of the two cases (No. 2 and 9) whose blood samples were available for the assay (0.38 vs 4.40 and 1.08 vs. 15.20 pg/ml, respectively).

**Discussion**

This study initially investigated baseline NK cell function in the monocytes/macrophages of breast cancer patients in comparison with the healthy women. The NK cytotoxic activity was significantly lower in Group 2 patients (Ramathibodi Hospital) while the activity in Group 1 patients was similar compared with the healthy subjects. This may suggest the difference in severity of breast cancer between the two groups of patients. In addition, conditions of stress and depression in the first group of patients before tumor operation may have influenced the immune status of the patients in Group 2 (Irwin et al., 1987; Levy et al., 1987; Talmadge and Alvord, 1987). The lytic figures were similar in all these three groups. Following treatment with the remedy for 1 and 2 weeks, NK cell activity in healthy subjects remained unchanged. On the other hand, significant increase in the cytotoxic activity (both as % cytotoxicity and lytic unit) was observed in Group 1 patients after the treatment with the remedy for two weeks. Altogether, this suggests that tumor cell is one of the key factors that play a role in challenging NK cell activity. With this limited sample size, the decline in NK cell activity (cytotoxic and lytic activities) when the courses of the conventional chemotherapeutics (A, and A+ B) were added to the treatment schedule of the remedy was not statistically significant. Direct comparative investigation (in two independent groups following the treatment with the remedy alone and in combination with chemotherapeutics) on the effect of chemotherapeutic alone and in combination with the remedy was not performed due to ethical concerns. Several medicinal plant extracts are currently receiving great attention for their enhancing effects on the immune effector function. This folk remedy may prove beneficial to patients who receive chemotherapeutics and/or surgery since it promotes the immune effector function. TNF-α, the cytokine produced by the human host, is a molecule that is involved in tumor cell killing as well as in a wide variety of biological activities (Lockslely et al., 2001). Results of the current preliminary study suggest the potential of the extract in stimulating the release of TNF-α from the monocytes/macrophages. Restoration of TNF-α release after the treatment with the remedy was also observed in all of the seven patients who had relatively low release in response to LPS stimulation at baseline. It was noted that 5 patients (No. 1, 9, 11, 12, and 13) whose tumor cells were still present at the time of blood collection for TNF-α release analysis, showed good activity of monocytes/macrophages in response to both LPS and treatment with the remedy. The addition of chemotherapeutic regimen A appears to decrease the release of TNF-α. Unfortunately this could be confirmed only by two cases whose blood samples were available.
for the assay. Results suggest that the presence of tumor cells can activate the response of monocyte/macrophage stimulation. A variety of immunological approaches for treating cancers including antitumor antibodies, adoptive cellular immunotherapy, and cytokine treatment are currently in clinical trials (Monjazeb et al., 2013). Several of these exogenous approaches are highly toxic at the doses required for tumor killing. The remedy enhanced both endogenous NK cell and monocyte/macrophage activity in the same manner as exogenous stimulating substances but without significant adverse effects during the course of the treatment. All patients had better tolerability to the chemotherapeutic courses in the presence of the remedy. Further studies in a larger sample size should be conducted to confirm the therapeutic efficacy and safety of the extract when used as adjuvant therapy with conventional chemotherapeutics and surgery. The use of the remedy as an adjunct therapy may improve therapeutic efficacy and safety profiles of conventional chemotherapeutic regimens through the stimulation immune status of cancer patients. Further study in a larger number of patients is required.

Acknowledgements

The study was supported by the China Medical Board, Siriraj Hospital and the Faculty of Graduate Studies, Mahidol University, Bangkok, Thailand.

References

Abe N, Ebina T, Ishida N (1982). Interferon induction by glycyrrhizin and glycyrrhetic acid in mice. Mikrobiol Immunol, 26, 535-9.
Boyum A (1968). Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab, 21, 77-89.
Burana-Osot J, Pattananayarat K, Soonthornchareonnon N, Sukapirom K, Toida T (2010). Characterisation and immunostimulating activity of polysaccharides from Thai medicinal plants. Nat Prod Res, 24, 1403-12.
Cerottini JC, Brenner KT (1974). Cell mediated cytotoxicity, allograft rejection and tumor immunity. Adv Immunol, 18, 67-72.
Hiserodt JC, Britvan LJ, Targan SR (1982). Inhibition of human natural killing by heterologous and monoclonal antibodies. J Immunol, 129, 2248-54.
Irwin M, Smith TL, Gillin JC (1987). Low natural killer cytotoxicity in major depression. Life Sci, 41, 2127-33.
Levy S, Herberman BB, Lippman M, D’Angelo T (1987). Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol, 5, 348-53.
Locksley RM, Killeen N, Lenardo MJ (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 104, 487-501.
Lozzio BB, Lozzio CB (1977). Properties of the K562 cell line derived from a patient with chronic myeloid leukemia. Int J Cancer, 19, 136-42.
McCaleb B (1989). Astragalus enhance natural killer cell activity. Herbalgram, 21, 16-21.
Monjazeb AM, Hsiao HH, Sckisel GD, Murphy WJ (2013). The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. J Immunotoxicol, 9, 248-58.
Na-Bangchang K, Wiwatwittaya S, Thongprasert S, et al (2012). Anticancer activity and immunostimulating effect on NK-cell activity of a well-known Thai folkloric remedy. Int Res J Pharm Pharmacol, 2, 1-11.
National Cancer Institute of Thailand. Cancer registry. http://www.nci.go.th/Rep.htm.
Pollock RE, Lotzová E (1987). Surgical-stress-related suppression of natural killer cell activity: a possible role in tumor metastasis. Nat Immun Cell Growth Regul, 6, 269-78.
Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS (1981). Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol, 1, 51-63.
Ruff MR, Gifford GE (1980). Purification and physicochemical characterization of rabbit tumor necrosis factor. J Immunol, 125, 1671-7.
Salagianni M, Baxevanis CN, Papamichail M, Perez SA (2012). New insights into the role of NK cells in cancer immunotherapy. Oncoimmunol, 1, 205-7.
Schmidt RE, MacDermott RP, Bartley G (1985). Specific release of proteo-glycans from human natural killer cells during target lysis. Nature, 318, 289-91.
Sun Y, Hersh EM, Talapaz M (1983). Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs. Cancer, 52, 70-3.
Talmadge JE, Alvord WG (1987). Stress factors and breast cancer outcome. J Clin Oncol, 5, 333-4.
Wagner K (1985). Immunostimulatory drugs of fungi and higher plants. In: economic and medicinal plant research Volume 1. Edited by Wagner H, Hikino H, and Farnsworth NR. New York: Academic Press, 113-53.
Yamada H, Kiyohara H, Cyang JC, Kojima Y, Kumezawa Y (1982). Studies on polysaccharides from Ngelica autiloba. Planta Med, 45, 163-7.